IHH HEALTHCARE |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.24 MYR | +0.97% |
|
+0.81% | +3.48% |
| May. 30 | IHH Healthcare's Q1 Attributable Profit Nearly Halves on Increased Spending | MT |
| May. 30 | Transcript : IHH Healthcare Berhad, Q1 2024 Earnings Call, May 30, 2024 |
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 29.97 and 28.13 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.48% | 11.7B | B+ | ||
| -26.11% | 15B | B+ | ||
| -0.90% | 11.99B | B | ||
| +5.21% | 10.27B | B+ | ||
| -6.29% | 7.5B | A- | ||
| +5.89% | 6.71B | B- | ||
| +0.89% | 6.02B | D | ||
| -4.31% | 4.28B | - | ||
| +9.52% | 4.04B | B+ | ||
| -10.61% | 3.97B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IHH Stock
- Ratings IHH Healthcare
